ARCA Biopharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ARCA Biopharma, Inc. - overview
Established
2004
Location
Westminster, CO, US
Primary Industry
Biotechnology
About
ARCA Discovery Inc. is a US-based biopharmaceutical company focused on developing innovative therapies for chronic conditions, with a particular emphasis on monoclonal antibodies for autoimmune diseases. Founded in 2004 in Westminster, US, ARCA Discovery Inc. specializes in the development of novel biopharmaceutical treatments.
The company completed an IPO in January 2009, solidifying its operations within the biopharmaceutical industry. While details on company pivots or subsidiaries are not specified, the company’s leadership and strategic direction are evident through its funding efforts. ARCA Discovery Inc. is engaged in developing advanced monoclonal antibodies aimed at treating chronic dermatological conditions such as plaque psoriasis and psoriatic arthritis.
Its lead product, ORKA-001, is currently undergoing Phase 2a clinical trials for moderate-to-severe plaque psoriasis, aiming to enhance patients' quality of life with minimal dosing requirements. In the most recent year, ARCA Discovery reported an EBITDA of USD 7. 185 mn. The company generates revenue through strategic partnerships and collaborations centered around the advancement of its therapeutic products, primarily focusing on its flagship product, ORKA-001, as it progresses through clinical trials and seeks regulatory approval.
ARCA Discovery Inc. plans to leverage recent funding of USD 37. 00 mn from its latest PIPE round, led by Venrock, to accelerate the development of ORKA-001 and other upcoming therapies. The company is focused on expanding its market presence in North America and Europe while aiming to initiate new product launches as they complete clinical trials.
The objective is to finalize product offerings and establish pricing strategies that ensure accessibility for patients once regulatory approvals are obtained.
Current Investors
Atlas Venture, Boulder Ventures, Pequot Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Cardiology
Website
www.arcabio.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
ARCA Biopharma, Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (6,759,000) | (4,276,000) | (6,914,000) | (9,614,000) | (11,247,000) | (16,132,000) | (18,237,000) | (8,094,000) | (5,725,000) | (9,673,000) | (19,244,000) | (10,482,000) | - | - | - |
| Operating Income (USD) | (7,361,000) | (4,319,000) | (6,940,000) | (9,693,000) | (11,455,000) | (16,613,000) | (18,712,000) | (8,118,000) | (5,814,000) | (9,766,000) | (19,335,000) | (10,596,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (5,364,000) | (4,320,000) | (6,939,000) | (9,689,000) | (11,445,000) | (16,444,000) | (18,490,000) | (7,933,000) | (5,482,000) | (9,738,000) | (19,322,000) | (9,926,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ARCA Biopharma, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.